drugset / Trial / NCT01270087
The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.
Phase 4
Completed
14 enrolled
Skane University Hospital
Abbott · collabCrafoord Foundation · collabThe Swedish Research Council · collabThe Swedish Rheumatism Ass · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Intravenous |